Requirement of BAX for TRAIL/Apo2L-induced apoptosis of colorectal cancers: Synergism with sulindac-mediated inhibition of Bcl-xL

Cancer Research

Volumn 62, Issue 6, 2002, Pages 1583-1587

  Ravi, Rajani ^a   Bedi, Atul ^a  

^a JOHNS HOPKINS UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CASPASE 8; CASPASE 9; NONSTEROID ANTIINFLAMMATORY AGENT; PROTEIN BAX; PROTEIN BCL XL; PROTEIN P53; SULINDAC SULFIDE; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND;

APOPTOSIS; ARTICLE; CANCER CELL CULTURE; COLORECTAL CANCER; COMPLEX FORMATION; CONTROLLED STUDY; ENZYME ACTIVATION; GENE LOSS; GENE MUTATION; GENOTYPE; HUMAN; HUMAN CELL; MITOCHONDRION; PRIORITY JOURNAL; PROTEIN EXPRESSION; RADIOSENSITIZATION;

ADENOCARCINOMA; AMINO ACID SEQUENCE; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ANTINEOPLASTIC AGENTS; APOPTOSIS; APOPTOSIS REGULATORY PROTEINS; BCL-2-ASSOCIATED X PROTEIN; BCL-X PROTEIN; COLORECTAL NEOPLASMS; DRUG SYNERGISM; GENES, P53; HUMANS; I-KAPPA B KINASE; MEMBRANE GLYCOPROTEINS; MOLECULAR SEQUENCE DATA; NF-KAPPA B; PROTEIN-SERINE-THREONINE KINASES; PROTO-ONCOGENE PROTEINS; PROTO-ONCOGENE PROTEINS C-BCL-2; RECOMBINANT PROTEINS; SULINDAC; TNF-RELATED APOPTOSIS-INDUCING LIGAND; TUMOR CELLS, CULTURED; TUMOR NECROSIS FACTOR-ALPHA;

EID: 0037085935     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (25)

1. Colon and rectum
2. Colorectal tumors
3. Ferredoxin reductase affects p53-dependent, 5-fluorouracil-induced apoptosis in colorectal cancer cells
4. Disruption of p53 in human cancer cells alters the responses to therapeutic agents
5. p53 gene mutations occur in combination with 17p allelic deletions as late events in colorectal tumorigenesis
6. Death receptors: Signaling and modulation
7. Safety and antitumor activity of recombinant soluble Apo2 ligand
8. Mammalian caspases: Structure, activation, substrates, and functions during apoptosis
9. Proapoptotic BAX and BAK: A requisite gateway to mitochondrial dysfunction and death
10. Somatic frameshift mutations in the BAX gene in colon cancers of the microsatellite mutator phenotype
11. Prevalence of ras gene mutations in human colorectal cancers
12. Expression of epidermal growth factor receptor in normal colonic mucosa and in adenocarcinoma of the colon
13. Regulation of death receptor expression and TRAIL/Apo2L-induced apoptosis by NF-κB
14. L
15. Bcl-2, bcl-x(1) sequester bh3 domain-only molecules preventing bax- and bak-mediated mitochondrial apoptosis
16. Role of BAX in the apoptotic response to anticancer agents
17. Selective inhibition of NF-κB activation by a peptide that blocks the interaction of NEMO with the IκB kinase complex
18. Inhibition of death receptor signals by cellular FLIP
19. NF-κB inducers upregulate cFLIP, a cycloheximide-sensitive inhibitor of death receptor signaling
20. Sulindac inhibits activation of the NF-κB pathway
21. Treatment of colonic and rectal adenomas with sulindac in familial adenomatous polyposis
22. Inhibition of apoptosis during development of colorectal cancer
23. Hypoxia-mediated selection of cells with diminished apoptotic potential in solid tumours
24. The effects of sulindac on colorectal epithelial proliferation and apoptosis in patients with familial adenomatous polyposis
25. Kinetics of the tissue distributions of sulindac and metabolites. Relevance to sites and rates of bioactivation